clinical trial · NCT04170153
Tuvusertib (M1774) in Participants With Metastatic or Locally Advanced Unresectable Solid Tumors (DDRiver Solid Tumors 301)
EMD Serono Research & Development Institute, Inc.·phase1·active not recruiting·n = 161
Metastatic or Locally Advanced Unresectable Solid TumorsM1774Niraparib
brief summary
This is an open-label, Phase I, first-in-human (FIH) multicenter, clinical study conducted in multiple parts to establish the safety, tolerability and pharmacokinetic/pharmacodynamic (PK/PD) profile (with and without food) and early signs of efficacy of Tuvuseritib (M1774) as monotherapy and in combination with the poly (ADP-ribose) polymerase (PARP) inhibitor niraparib.
started
Dec 20, 2019
primary completion
Nov 30, 2026
completion
Nov 30, 2026
last updated
Aug 13, 2026
official title
An Open-label, Multicenter Trial of the Safety, Tolerability, and Pharmacokinetic/Pharmacodynamic Profile of Tuvusertib (M1774) in Participants With Metastatic or Locally Advanced Unresectable Solid Tumors (DDRiver Solid Tumors 301)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol